Abstract
Survivin, a member of the inhibitory apoptosis protein family, gives rise, by an alternative splicing, to four variants with different functions. Many experimental studies indicate that p53 can regulate the expression of survivin and some of its splice variants. Although both the expression of survivin splice variants and the p53 gene were frequently altered in human cancers, nothing is known about their interactions in in vivo tumour samples. Here, we report that, in 162 breast carcinomas, p53 mutations are significantly associated with an increased expression of survivin and, in particular, its antiapoptotic splice variants (survivin-ΔEx3 and survivin-3B). The upregulation of these variant expressions is particularly related to p53 mutations occurring in the residues belonging to the tetramerization domain. The loss of heterozygosity in the p53 gene is also associated with an increased expression of the survivin-ΔEx3 variant. The expression of the proapoptotic variants (survivin-2B and survivin-2α) is not affected by any of these alterations. Our results provide for the first time in vivo evidence that, in human breast cancer, the survivin expression as well as its splicing depends on the p53 status. The results also suggest that the upregulation of antiapoptotic survivin variant expression by the mutant p53 may increase breast cancer cells survival and resistance to therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Altieri DC . (2003). Nat Rev Cancer 3: 46–54.
Ambrosini G, Adida C, Altieri DC . (1997). Nat Med 3: 917–921.
Ambrosini G, Adida C, Sirugo G, Altieiri DC . (1998). J Biol Chem 273: 11177–11182.
Badran A, Yoshida A, Ishikawa K, Goi T, Yamagushi A, Ueda T et al. (2004). Biochem Biophys Res Commun 314: 902–907.
Bullok AN, Fersht AR . (2001). Nat Rev Cancer 1: 68–76.
Caldas H, Honsey LE, Altura RA . (2005). Mol Cancer 4: 11–20.
Cawkwell L, Lewis FA, Quirke T . (1994). Br J Cancer 70: 813–818.
Cho Y, Gorina S, Jeffrey PD, Pavletich NP . (1994). Science 265: 336–355.
Dumont P, Leu JI, Della Pietra III AC, George DL, Murphy M . (2003). Nat Genet 33: 357–365.
Estève PO, Chin HG, Pradhan S . (2005). Proc Natl Acad Sci USA 102: 1000–1005.
Franco N, Arnould L, Mege F, Picard SF, Arveux P, Lizard-Nacol S . (2003). Arch Surg 138: 291–295.
Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M . (2002). J Biol Chem 277: 3247–3257.
Livak KJ, Schmittgen TD . (2001). Methods 25: 402–408.
Lohr K, Moritz C, Contente A, Dobbelstein M . (2003). J Biol Chem 278: 32507–32516.
Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD . (1999). Cancer Res 59: 6097–6102.
Maxwell SA, Acosta SA, Davis GE . (1999). Apoptosis 4: 109–114.
Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S et al. (2002). Oncogene 21: 2613–2622.
Moyret-Lalle C, Duriez C, Kerckhove JV, Gilbert C, Wang Q, Puisieux A . (2001). Cancer Res 61: 486–488.
Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ et al. (1999). Genes and Dev 13: 2490–2501.
Nasu S, Yagihashi A, Izawa A, Saito K, Asanuna K, Nakamura M et al. (2002). Anticancer Res 22: 2613–2622.
O'Driscoll L, Linehan R, Kennedy SM, Cronin D, Purcell R, Glynn S et al. (2003). Cancer Lett 201: 225–236.
Punga T, Akusjarvi G . (2003). FEBS Lett 552: 214–218.
Ryan B, O'Donovan N, Browne B, O'Shea C, Crown J, Hill ADK et al. (2005). Br J Cancer 92: 120–124.
Sommer KW, Schamberger CJ, Schmidt GE, Sasgary S, Cerni C . (2003). Oncogene 22: 4266–4280.
Soussi T, Beroud C . (2001). Nat Rev Cancer 1: 233–240.
Tran J, Master Z, Yu J, Rak J, Dumont D, Kerbel R . (2002). Proc Natl Acad Sci USA 99: 4349–4354.
Tsuji N, Furuse K, Asanuma K, Furuya M, Kondoh K, Kamagata C et al. (2004). Breast Cancer Res Treat 87: 23–31.
van Oijen GCT, Slootweg PJ . (2000). Clin Cancer Res 6: 2138–2145.
Végran F, Boidot R, Oudin C, Riedinger JM, Lizard-Nacol S . (2005). Int J Oncol 27: 1151–1157.
Xu M, el-Gewely MR . (2003). Oncol Res 13: 429–436.
Yoon H, Liyanarachci S, Wright FA, Davaluri R, Lockman JC, de la Chapelle A et al. (2002). Proc Natl Acad Sci USA 99: 15632–15637.
Zhou X, Wang XW, Xu L, Hagiwara K, Ngashima M, Wolkowicz R et al. (1999). Cancer Res 59: 843–848.
Zhu N, Gu L, Findley HW, Li F, Zhou M . (2004). Oncogene 23: 7545–7551.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Végran, F., Boidot, R., Oudin, C. et al. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 26, 290–297 (2007). https://doi.org/10.1038/sj.onc.1209784
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209784
Keywords
This article is cited by
-
Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma
Cellular & Molecular Biology Letters (2017)
-
Survivin splice variants and their diagnostic significance
Tumor Biology (2015)
-
Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors
Breast Cancer Research (2014)
-
Transcriptional regulation of the survivin gene
Molecular Biology Reports (2014)
-
Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells
Cancer Gene Therapy (2013)